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Parkinson’s disease (PD) is a progressive neurodegenerative disorder of unclear etiology and pathogenesis. Research results gathered 
to date support the hypothesis that the motor symptoms of the disease result from the gradual loss of midbrain dopamine neurons 
residing in the substantia nigra pars compacta (SNpc). Recent discoveries, however, significantly expand this knowledge indicating that 
the primary source of the PD pathogenesis may be located both in the SNpc as well as in the GABAergic striatum. Newly discovered 
striatal neurogenesis – normally a lifelong process – determines the efficiency of nigrostriatal interaction. Deficient neurogenesis within 
the striatum followed by a decline in the GABAergic/dopaminergic interaction results in progressive disconnection of the dopaminergic 
input, which initiates a  ‘vicious circle’ cascade of neuronal damage. Effects of both deficient striatal neurogenesis and age‑related 
neurodegeneration within the striatum accumulate, resulting in a progressive decline in the control functions of the basal ganglia, 
loss of dopaminergic neurons, and occurrence of PD clinical symptoms. Functional and pharmacological control of these dynamic 
relationships may result in treatments that are more effective with fewer side‑effects. 
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Nigrostriatal interaction and neurodegenerative 
disorders
Neurodegenerative diseases constitute a heterogeneous 
group of age‑related disorders that are characterized by 
a slow but irreversible deterioration of brain functions. 
Parkinson’s disease (PD) represents the second most common 
neurodegenerative disorder that is clinically characterized 
by non‑motor and motor symptoms (Błaszczyk 1998, 
Chaudhuri et al. 2006, Pellicano et al. 2007, Schapira 2008, 
Yadav and Li 2015). The etiology and pathogensis of PD still 
remains unclear, but it is thought that it may be caused by 
a combination of genetic and environmental factors (Braak 
et al. 2004, Schapira 2007, Mosharov et al. 2009, Brichta 
and Greengard 2014, Yadav and Li 2015, Goedert 2015). It 
is well documented that the cardinal features of PD motor 
symptoms including bradykinesia, muscular rigidity, rest 
tremor, and postural and gait instability can be entirely 
explained by degeneration of dopaminergic neurons 
in the substantia nigra pars compacta (SNpc) (Cenci 2007, 
Pellicano et al. 2007, Fahn 2008, Brichta and Greengard 
2014, Yadav and Li 2015). Consequently, treatment for PD 
has classically involved supplementation of endogenous 
dopamine (DA) with medicinal options that either replace 
dopamine or augment the nigrostriatal dopaminergic 
pathway (Schapira 2007, Fahn 2008, Yadav and Li 2015). 
Surprisingly, all current pharmacological therapies and 
surgical treatments, including deep brain stimulation 
and stem cell therapy, are oriented towards symptomatic 
relief and do not cure disease (Schapira 2007, Yadav and Li 
2015). Our current knowledge why the SNpc dopaminergic 
neurons are particularly vulnerable to degeneration 
is still extremely limited (Pissadaki and Bolam 2013, 
Brichta and Greengard 2014, Dopeso‑Reyes et al. 2014), 
and without this knowledge, development of a promising 
neuroprotective treatment strategy is not possible. For 
instance, intracellular calbindin content in addition to 
the relatively high energy cost of neuronal activity may 
be clues to the susceptibility of midbrain DA neurons to 
neurodegeneration (Pissadaki and Bolam 2013, Brichta 
and Greengard 2014, Dopeso‑Reyes et al. 2014). The latter 
factor, i.e. the neuronal activity is strongly controlled by 
the GABAergic system (Błaszczyk et al. 2016). That is why 
decline in GABA inhibitory function may initiate/escalate 
neurodegenerative processes both in the striatum and 
the SNpc, thus leading to the development of pathologies 
such as Parkinson’s disease (Błaszczyk 2016). In particular, 
GABAergic input of the striatum with its fragile and 
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sophisticated nigrostriatal interaction may be a primary 
locus for the pathology. 
The striatum is a major portion of the basal ganglia 
that forms their GABAergic input (Cicchetti et al. 2000, 
Grillner et al. 2005, Brichta and Greengard 2014, Ernst 
et al. 2014). It is functionally subdivided into ventral 
and dorsal areas which participate in different aspects 
of motor control (Koós and Tepper 1999, Rodrigo et 
al. 2002, Grillner et al. 2005, Wesson and Wilson 2011, 
Brichta and Greengard 2014). The ventral striatum 
functions as part of the reward system and is mostly 
involved in the motivational/emotional modulation of 
motor behavior. Here, dopaminergic projections from the 
nucleus accumbens and the SNpc are used to integrate 
the emotional and motivational salience of multi‑sensory 
input with reinforcement and to reward perception 
related to motor activity (Grillner et al. 2005). Dysfunction 
of the ventral striatum is probably responsible for PD 
premotor symptoms (Chaudhuri et al. 2006).
The second part, the dorsal striatum is directly involved in 
the main aspects of motor control including motor program 
selection, activation, and execution (Cicchetti et al. 2000, 
Grillner et al. 2005, Cenci 2007). Neural processes involved in 
selection and activation of a context‑specific motor program 
are based upon the integration of motivational/emotional 
signaling with sensory‑motor inputs (Wesson and Willson 
2011, Yager et al. 2015). In order to execute a relevant 
motor program, it must be released from the pallidal 
inhibition through activation of the nigrostriatal input. 
For this purpose, the SNpc dopaminergic neurons provide 
the massive excitatory projection to the dorsal striatum 
(Grillner et al. 2005, Ibáñez and Andressoo 2017). Axons of 
this pathway synapse onto GABAergic striatal medium spiny 
neurons (MSNs) and thus gain access to the main functions 
of motor control. This unique synaptic junction between 
the GABAergic and dopaminergic systems, results in a close 
and specific functional interaction between both systems, 
including the process of nigrostriatal synaptogenesis and 
continuous cellular turnover of striatal interneurons (Dayer 
et al. 2005, Curtis et al. 2011, Wang et al. 2011, Ernst et al. 
2014, Adlaf et al. 2016). Consequently, the motor symptoms 
of Parkinson’s disease may be due both to the dysfunction 
of dopaminergic SNpc or to the GABAergic striatum. 
In particular, parkinsonian akinesia may be attributed 
to an imbalance between movement‑suppressing and 
movement‑promoting pathways within the basal ganglia 
(Damodaran et al. 2014). To verify this claim, we must look 
closer at the phenomena of nigrostrial interaction and 
particularly their striatal contributions.
The MSNs make up 75–80% of the striatal input 
neuronal cells, and the four subtypes of interneurons 
together represent 20–25% of the striatum (Cicchetti et al. 
2000, Tepper and Bolam 2004). Both the neurons and the 
interneurons of the striatum are inhibitory and use GABA 
as their main neurotransmitter. It has been documented 
that the medium spiny neurons do not degenerate and 
their population in the adult human brain is not renewed 
to a significant level (Cenci 2007, Curtis et al. 2011, Ernst 
et al. 2014). On the contrary, the GABAergic interneurons, 
although in the minority, appear to play a fundamental role 
in the physiology and pathophysiology of the nigrostriatal 
input (Wang et al. 2011, Ernst et al. 2014, Adlaf et al. 2016). 
In order to function correctly, the striatal input must be 
protected against unwanted, accidental activation (Grillner 
et al. 2005). During resting conditions that are characterized 
by a mild tonic dopaminergic activation (Brichta and 
Greengard 2014), the medium spiny neurons must be kept 
in a silent ‘hyperpolarized state’ until they receive a robust 
excitatory dopaminergic input (Domodaran et al. 2014, Hu 
et al. 2014). 
It has been documented that nigrostriatal‑projecting 
neurons express a lower level of calbindin and thus are 
particularly prone to degeneration due to neurotoxins, 
excitotoxicity or aging (Brichta and Greengard 2014, 
Dopeso‑Reyes et al. 2014). The dopaminergic neuron 
activity is driven by calcium channels (Brichta and 
Greengard 2014). In such conditions, both the level and the 
threshold of striatal input is effectively controlled just by 
the network of GABAergic interneurons (Damodaran et al. 
2014). As depicted graphically in Fig. 1, sparsely represented 
parvalbumin‑expressing fast‑spiking interneurons (FSI), 
constituting only about 0.7% of striatal neurons exert 
a powerful and decisive impact on the nigrostriatal input 
(Cicchetti et al. 2000, Hu et al. 2014). The FSIs synapse on the 
striatal MSNs, projecting mainly to their somas and proximal 
dendrites (Koós and Tepper 2002, Cicchetti et al. 2000, 
Yager et al. 2015). In this way, fast‑spiking interneurons can 
efficiently control the excitability of the MSNs (Damodaran 
et al. 2014). Moreover, a single FSI can block or delay the 
firing of more than 100 medium spiny projection neurons 
(Koós and Tepper 2002). 
Each MSN receives a vast amount of input from different 
incoming DA axons. It is estimated that a single medium 
spiny GABAergic neuron may receive synaptic input 
from more than 200 SNpc dopaminergic cells (Ibáñez and 
Andressoo 2017). Consequently, the axonal tree of each 
individual SNpc dopaminergic neuron branches extensively 
onto the GABAergic medium spiny neurons covering on 
average, 1.5% of the total striatal volume (Ibáñez and 
Andressoo 2017). This redundancy explains the remarkable 
compensatory capacity of the nigrostriatal control and the 
fact that motor deficits of PD do not become symptomatic 
until more than 30–40% of SNpc neurons are lost. It should 
be mentioned here, that acetylcholine is also one of the 
main modulators of striatal fast‑spiking interneurons, 
contributing greatly to the powerful modulation of 
GABAergic synaptic transmission between FSIs and spiny 
projection neurons (Koós and Tepper 2002). 
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The emergent properties of the nigrostriatum 
are determined by multi‑level and multi‑functional 
interaction between the dopaminergic and GABAergic 
systems. Most importantly, impairment and progressive 
decline of the nigrostrital interaction can be initiated 
from either systems: dopaminergic or GABAergic. In the 
former case, the DA neuron degeneration may be triggered 
by mitochondrial neurotoxins such as MPP+ or rotenone 
that results in parkinsonism (Brichta and Greengard 
2014). Also, reliance of SNpc dopaminergic neurons on 
calcium for their spontaneous activity in combination with 
a relatively lower level of intracellular calbindin makes 
them extremely prone to age‑related degeneration (Brichta 
and Greengard 2014, Pisadaki and Bolam 2013). In this case, 
the elevated oxidative stress and formation of Lewy bodies 
could initiate a ‘vicious circle’ of DA neuronal insult and 
progressive neurodegeneration. Importantly, the process 
of DA neurodegeneration may be triggered, as well, by the 
decline of GABA neuron turnover in the striatum.
Fragile balance between neurodegeneration and 
neurogenesis in the striatum
Two fundamental properties of the nigrostriatal 
input: its adaptivity and synaptic plasticity, allow 
continuous adjustment of the threshold, sensitivity and 
selectivity of the input depending on the behavioral 
context including individual motor experience 
and learning. These properties are fundamentally 
determined by the anatomy of the nigrostriatal input 
and its propensity to adaptive remodeling (Ernst et al. 
2014, Adlaf et al. 2016, Ibáñez and Andressoo 2017). In 
contrast to the medium spiny projection neurons, the 
GABA interneurons and their supportive, non‑neuronal 
cells (a subset of short‑lived oligodendrocytes), are 
prone to neurodegeneration (Ernst et al. 2014). However, 
lost interneurons and oligodendycytes are constantly 
replaced with new ones in the process of striatal cell 
turnover (Bédard et al. 2002, Brazel et al. 2003, Dayer 
et al. 2005, Wang et al. 2011, Ernst et al. 2014, Adlaf et 
al. 2016). In humans, the subventricular zone (SVZ) 
is a specialized area containing self‑renewing GFAP+ 
astrocytes functioning as neural stem cells that generate 
new GABA fast‑spiking interneurons in the striatum 
throughout life (Brazel et al. 2003, Adlaf et al. 2016). In 
the adult human striatum, the median turnover rate 
of interneurons is comparable to the turnover rate of 
neurons within the hippocampus (Ernst et al. 2014). 
The aging of the brain appears, among other to be 
related to a decline of striatal cell turnover (Strömberg et al. 
1993, Koós and Tepper 2002). GABA interneuron turnover 
is fundamental for motor control and its deficiency due 
to aging is probably the main cause for the development 
Fig.  1. Heuristic model of the nigrostriatal interaction showing the 
physiology (A) and pathophysiology (B) of the striatum that may cause 
Parkinson’s disease. In physiological conditions, the interaction is 
determined by the activity‑dependent continuous turnover of GABAergic 
interneurons of the striatum. The parvalbumin expressing fast‑spiking 
interneurons (FSI) are susceptible to apoptosis thus physiological 
function of the striatum requires rapid and continuous exchange of these 
interneurons. Normal activity of the striatum that is characterized by an 
elevated level of neurotransmitters (mostly GABA) and the glia‑derived 
neurotrophic factor (GDNF) intensifies proliferation and migration of stem 
cells to the striatum. The subventricular (SVZ) is a specialized brain area 
containing self‑renewing GFAP+ astrocytes functioning as neural stem 
cells that generate new FSIs in the striatum throughout life. Deficient 
neurogenesis within the striatum followed by a decline in the nigrostriatal 
interaction results in progressive withdrawal and eventually disconnection 
of the dopaminergic input from the substantia nigra pars compacta (SNpc). 
This initiates a  ’vicious circle’ cascade of pathological events resulting 
in a  devastating decline of nigrostriatal interaction that leads to a  fatal 
damage of the FSI turnover and neurodegeneration of the DOPA neurons 
of the SNpc. In this pathological state, the striatum loses its control over 
the pallidal output and clinical symptoms of full‑blown Parkinson’s disease 
(including the bradykinesia, tremor, rigidity) are observed.
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of PD clinical symptoms (Androutsellis‑Theotokis et 
al. 2009, Zachrisson et al. 2011, Ibáñez and Andressoo 
2017). In fact, it became evident recently that 
deficient neurogenesis within the striatum followed 
by a decline in the nigrostriatal interaction results in 
progressive withdrawal and eventual disconnection of 
the dopaminergic synapsis. A deficient nigrostriatal 
input, in turn, results in progressive neuronal damage 
(Ibáñez and Andressoo 2017). The striatal input network 
(structured from MSNs) deprived from FSI inhibition, 
initially becomes overactive. This impairs its function 
(i.e. selective control of the pallidal output). It also makes 
the MSNs more susceptible to neurodegeneration (likely 
due to energy deficiency, as suggested by Pissadaki and 
Bolam 2013) that, in a longer perspective, leads to damage 
of the basal ganglia. 
Early effects of neurodegeneration within the 
nigrostriatal input are, at least partially, compensated 
by the process of synaptic reorganization that usually 
requires an enforced activity of the medium spiny neurons 
(Adlaf et al. 2016). For instance, it has been documented in 
the PD rodent models that the axonal trees of the surviving 
dopaminergic axons can re‑innervate the nigrostriatal 
synapses left vacant by the degenerating GABA neurons 
(Ibáñez and Andressoo 2017). 
Striatal neurogenesis in humans appears to be 
a productive lifelong process whose understanding may 
provide the opportunity to manage neurodegenerative 
disorders (Wei et al. 2011, Zachrisson et al. 2011, Göritz 
and Frisén 2012). In the process of striatal cell turnover, 
the glial cell‑derived neurotrophic factor (GDNF) seems 
to play a pivotal role (Lin et al. 1993, Strömberg et al. 
1993, Lapchak et al. 1996, 1997, Cohen et al. 2003, Ibáñez 
and Andressoo 2017). In the striatum, the GDNF is 
predominantly expressed by GABA interneurons. 
In the process of neurogenesis, GDNF promotes 
the functional and morphological differentiation 
of GABAergic neurons (Ibáñez and Andressoo 2017, 
Marsh and Blurton‑Jones 2017). GDNF also functions as 
a chemoattractant, stimulating both (i) the proliferative 
stem cells of the SVZ to migrate and form interneurons 
in the adjacent striatum, and (ii) the synaptogenesis and 
DOPA/GABA re‑innervation (Adlaf et al. 2016, Ibáñez and 
Andressoo 2017). 
A growing body of evidence suggests that SVZ neural 
stem cell proliferation and migration is controlled by both 
neurotransmitters (DA and GABA) that determine striatal 
neuronal activity (Zachrisson et al. 2011, Adlaf et al. 2016). 
They are both dependent on the overall motor activity 
of a patient. Importantly, it seems well‑documented that 
cytokines from apoptotic neurons may initiate the process 
of striatal cell turnover. Thus, an increased SVZ proliferation 
follows striatal neuron death (Brazel et al. 2003, Adlaf 
et al. 2016). In the other words, neurodegeneration of 
striatal GABA interneurons initiates neurogenesis that 
compensates for the loss of fast‑firing interneurons. 
Neurogenesis in the adult brain serves to maintain 
a pool of striatal interneurons with unique properties that 
are present for a limited time and enable specific types 
of neural processing (Ernst et al. 2014). We can currently 
only speculate about the aspects of continuous striatal 
neurogenesis in humans, and the functional integration of 
the new neurons into existing neuronal circuits (Borel and 
Götz 2014). This process requires further research but data 
gathered so far allows us to posit that dysfunction of the 
striatum may be a primary cause of Parkinson’s disease. We 
should remember, however, that brain aging and related 
neurodegenerative processes are very complex and may 
result from the interaction of various, seemingly unrelated, 
physiological mechanisms. For instance, virtually all PD 
patients develop sleep disturbances at the early stage of 
the disease (Chaudhuri et al. 2006). The disturbances have 
a multifactorial etiology, but early degeneration of the locus 
coeruleus noradrenergic system (Samuels and Szabadi 
2008) and the serotonergic system related to the dorsal 
raphe nucleus (Grosch et al. 2016) may be of particular 
importance for the pathology. Their dysfunctions result in 
a decline of the restorative function of sleep that may cause 
accumulation of potentially neurotoxic waste products 
within the CNS (Xie et al. 2013). This, in turn, may escalate 
neurodegeneration and limit neurogenesis within the 
aging brain.
Can we cure Parkinson’s disease?
Therapeutic interventions that slow the progressive 
neurodegeneration within the nigrostriatal system or 
restore its normal function (neurorescue) depend on 
a clear understanding of the etiology and pathogenesis 
of PD (Schapiro 2007). Recognizing the existence of 
striatal neurogenesis and identifying factors that 
promote the renewal of striatal neurons may facilitate 
the development of new therapeutic strategies. Finding 
that neurons are added continuously in the adult human 
striatum poses the question of whether this process can 
be utilized therapeutically in Parkinson’s disease. Studies 
in rodents confirmed that promoting cell proliferation 
in the subventricular zone can have a positive effect in 
models of Parkinson’s disease, likely mediated by the new 
cells having a neurotrophic effect on the nigro‑striatal 
system (Androutsellis‑Theotokis et al. 2009, Zachrisson et 
al. 2011).
It has been shown recently that the neural stem 
cells within the striatum respond directly to GABA 
(Adlaf et al. 2016). Consequently, inserting glutamic acid 
decarboxylase (GAD) gene into the subthalamic nucleus 
seems to offer an alternative therapeutic strategy (LeWitt 
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et al. 2011). In the brain, GAD synthesizes GABA using the 
active form of vitamin B6 as a cofactor. Therefore, this 
therapeutic strategy restores local GABA transmission 
within the subthalamic nucleus and normalizes output 
from the nucleus by adding an inhibitory GABA outflow, 
thereby reducing excessive excitatory glutamate output 
to key targets such as the globus pallidus interna and the 
substantia nigra pars reticulata (LeWitt et al. 2011).
As mentioned above, GDNF has regenerative properties 
for brain cells showing potential in the treatment of PD 
(Lapchak et al. 1996, 1997, Cohen et al. 2003, Kirik et al. 2004, 
Eserian 2013, Marsh and Blurton‑Jones 2017). GDNF was 
discovered while searching for a neurotrophic factor for 
substantia nigra dopamine neurons (Lin et al. 1993). So far, 
it has been well documented that GDNF is involved in the 
development of the dopaminergic pathways and regulates 
DA cells apoptosis in the substantia nigra (Mosharov et al. 
2009). Dopaminergic neurons of the SNpc express both 
GDNF receptors: tyrosine kinase RET and GDNF Family 
Receptor alfa1 (GFRα1) (Ibáñez and Andressoo 2017). RET 
is the main GDNF receptor in the midbrain dopaminergic 
neurons that project to the striatum. 
In the striatum, GDNF is predominantly expressed by 
parvalbumin positive interneurons. Interestingly, GDNF 
delivery into the striatum, but not to the SNpc, results in 
functional recovery in rodent PD models, underlying the 
importance of GDNF delivery to its physiological site of 
expression for the treatment of PD (Kirik et al. 2004). In 
vitro studies demonstrated that GDNF can promote the 
functional and morphological differentiation of GABAergic 
neurons and function as a chemoattractant for GABAergic 
cells in explants from the subventricular zone (Paratcha et 
al. 2006). Thus GDNF signaling through RET is fundamental 
for long‑term maintenance of the dopaminergic 
nigrostriatal projection. Additionally, GDNF/GFRα1 
signaling is involved in axonal outgrowth and promotes 
synapse formation within the striatal input (Ernst et al. 
2014). Recent studies confirm a role for GDNF/GFRα1 
signaling in the development and function of multiple 
classes of GABAergic neurons in the mammalian brain. 
In particular, the GFRα1 contributes to the development 
and allocation of parvalbumin expressing fast‑spiking 
GABAergic interneurons (Ibáñez and Andressoo 2017). 
Unfortunately, progress in the development of the new 
GDNF pharmacotherapy is progressing slowly because 
GDNF does not cross the blood‑brain barrier. 
There is growing evidence that vitamin D increases the 
levels of tyrosine hydroxylase expression, suggesting that 
it might modulate dopaminergic processes (Eserian 2013). 
Vitamin D is a potent inducer of endogenous GDNF, and the 
most prominent feature of GDNF is its ability to support 
the survival of dopaminergic neurons. Thus, supportive 
therapy with vitamin D may prove to be useful in PD 
(Eserian 2013).
Another therapeutic aspect of adult GDNF expression 
and function is the possibility of its regulation with 
physical activity (Brazel et al. 2003, Cohen et al. 2003, Adlaf 
et al. 2016). Studies in rodents have shown upregulated 
GDNF expression in several CNS structures following 
increased motor activity. In particular, striatal GDNF 
level was found to be dramatically increased (Cohen et al. 
2003). This implies simply that GDNF expression leading to 
intrinsic neuroprotective and neuroregenerative outcomes 
may be therapeutically regulated by physical activity. 
Because GDNF potentiates and attracts striatal dopamine 
input, it is tempting to hypothesize that physiologically 
(e.g. by physical activity) or pharmacologically enforced 
neurogenesis of GDNF‑expressing interneurons in the 
striatum will induce re‑growth of the degenerating 
dopaminergic system in the aging brain (Ibáñez and 
Andressoo 2017).
Finally, we should mention here recent studies 
suggesting the important functions of the GDNF/
RET signaling system in the integrity and function of 
the blood‑brain barrier (Ibáñez and Andressoo 2017). 
The results indicate that GDNF may be an important 
up‑regulator of microglial activation and suggest that GDNF 
may offer protection from neurodegeneration through the 
inhibition of neuroinflammation (Morale et al. 2006, Ibáñez 
and Andressoo 2017).
CONCLUSIONS
The results of research on the pathogenesis of 
idiopathic Parkinson’s disease gathered so far, allow 
one to posit that the initial locus of the pathology 
is decline of the nigrostratial interaction that may 
be triggered among others by faulty turnover of the 
striatal GABA interneurons. Adult striatal neurogenesis 
in humans appears to be a productive lifelong process. 
It has been retained during human evolution, to provide 
movement adaptability. Continuous turnover of GABA‑
‑interneurons seems essential for activity‑dependent 
adaptive remodeling of the striatal system. Firstly, 
it contribute to functional adjustment of the striatal 
input: it controls its gain, the input threshold and 
selectivity. Secondly, it determines efficiency of network 
remodeling and adaptability during motor learning. In 
this context the striatum should be considered as a part 
of ‘movement memory system’. It adjusts functioning of 
the nigrostriatal input to individual’s motor behavior. 
Unfortunately, the latter interaction seems to be an 
additional factor that makes the nigrostriatal system 
more vulnerable to neurodegeneration. It initiates 
a ‘vicious circle’ cascade of neurodegenerative 
processes, including progressive withdrawal of 
dopaminergic synaptic input to the striatum, leading 
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inevitably to decreased motor activity. This, in turn, 
decreases GDNF expression within the striatum that 
results in progressive damage to both the striatal 
neuronal turnover and the dopaminergic input. This 
process is manifested initially by non‑motor symptoms 
and then spreads into the dorsal striatum, resulting 
in the appearance of motor symptoms. Therefore, the 
search for new therapies in PD should now focus on 
the GABAergic striatum. In the light of the present 
knowledge, however, it would be rather naive to posit 
that we can stop or totally reverse the ageing and all 
neurodegenerative processes within the brain. However, 
if we manage to slow down functional decline of the 
nigrostriatal interaction we will be able to improve 
quality of life of millions patients with idiopathic PD.
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